EF Hutton Maintains Buy on Trevi Therapeutics, Maintains $21 Price Target
Portfolio Pulse from Benzinga Newsdesk
EF Hutton analyst Jason Kolbert has reiterated a Buy rating for Trevi Therapeutics (NASDAQ:TRVI) and maintained a price target of $21.
October 04, 2024 | 3:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
EF Hutton's analyst Jason Kolbert has reiterated a Buy rating for Trevi Therapeutics, maintaining a price target of $21. This suggests confidence in the company's future performance.
The reaffirmation of a Buy rating and a $21 price target by EF Hutton indicates a positive outlook on Trevi Therapeutics' stock. This can lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100